OP-1074 exemplifies our hypothesis by exhibiting considerable potencies, both in tamoxifen-resistant MCF-7 cells and in breast cancer cells expressing the activating ERα Y537S somatic mutation. This evidence concerns the gene ESR1 and breast carcinoma.